

## Special Issue

# Chimeric Vaccines against Hyper Evolving Pathogens

### Message from the Guest Editors

Chimeric vaccines can be an effective strategy to combat infectious diseases. The conventional examples include the RTS/S vaccine, which the World Health Organization has recommended for pilot implementation against malaria. The chimeric vaccine approach has also been employed in the FDA-approved vaccine BEXSERO against *Neisseria meningitidis* serogroup B. BEXSERO includes the chimeric fused antigen of Neisserial Heparin Binding Antigen from strain NZ98/254 and accessory protein 953 from strain 2996. This Special Issue invites high-quality research in the development of chimeric vaccine and epitope variations in the newer strains/serotypes of various pathogens. This will include immune determinant polymorphisms' epidemiology, computational design/screening, mice studies, rational vaccine design and development, immune cell type response and field studies.

---

### Guest Editors

Dr. Yash Gupta

Department of Medicine, Penn State College of Medicine, Hershey, PA 17033, USA

Dr. Manish Manish

School of computational and integrative sciences, Jawaharlal Nehru University, New Delhi, India

---

### Deadline for manuscript submissions

closed (10 February 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/137482](https://mdpi.com/si/137482)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).